BMRN

#761
BioMarin Pharmaceutical Inc. - Common Stock
57.2 9 USD
+8.77%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
57.29
57.29
Rango anual
49.26
66.28
Cambio diario
+8.77%
Variación mensual
+5.60%
Variación en los últimos 6 meses
+3.23%
Cambio anual
-2.02%
Cierres anteriores
52.6 7
Open
57.2 9
Mínimo
57.2 9
High
57.2 9
Volumen
194
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 11.07 B
  • Employee 3 221
  • Founded N/A
  • CEO Alexander Hardy
  • Website www.biomarin.com
  • Headquarter Delaware, United States
  • FIGI BBG000CZWZ05
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
33.02
Relación precio/flujo de caja
3.64

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.

Noticias